Detection of biologically active botulinum neurotoxin-A in serum using high-throughput FRET-assay

Journal of Pharmacological and Toxicological Methods

Volumn 65, Issue 1, 2012, Pages 8-12

  Joshi, Suresh G ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Botulinum toxin; Botulism; Fluorigenic substrate; FRET assay; Pharmacokinetics

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; LIGHT CHAIN A; NEUROTOXIN; UNCLASSIFIED DRUG;

ARTICLE; BIOASSAY; BIOLOGICAL ACTIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; INTERMETHOD COMPARISON; MURINE PHRENIC NERVE HEMIDIAPHRAGM BIOASSAY; NONHUMAN; RAT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BOTULINUM TOXINS, TYPE A; COST-BENEFIT ANALYSIS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH-THROUGHPUT SCREENING ASSAYS; MICE; NEUROTOXINS; PHRENIC NERVE; RATS; SPECIES SPECIFICITY; TIME FACTORS;

MURINAE; RATTUS;

EID: 84857043173     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2011.11.002     Document Type: Article

References (19)

1. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA: The Journal of the American Medical Association 2001, 285(8):1059-1070. [Consensus Development Conference Research Support, Non-U.S. Gov't Review].
2. Bagramyan K., Barash J.R., Arnon S.S., Kalkum M. Attomolar detection of botulinum toxin type A in complex biological matrices. PLoS One 2008, 3(4):e2041. [Research Support, N.I.H., Extramural]. 10.1371/journal.pone.0002041.
3. Baldwin M.R., Bradshaw M., Johnson E.A., Barbieri J.T. The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability. Protein Expression and Purification 2004, 37(1):187-195. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.]. 10.1016/j.pep.2004.05.009.
4. Boldt G.E., Kennedy J.P., Hixon M.S., McAllister L.A., Barbieri J.T., Tzipori S., et al. Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. Journal of Combinatorial Chemistry 2006, 8(4):513-521. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1021/cc060010h.
5. DasGupta B.R., Foley J. C. botulinum neurotoxin types A and E: isolated light chain breaks down into two fragments. Comparison of their amino acid sequences with tetanus neurotoxin. Biochimie 1989, 71(11-12):1193-1200. [Comparative Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
6. Fernandez-Salas E., Steward L.E., Ho H., Garay P.E., Sun S.W., Gilmore M.A., et al. Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(9):3208-3213. 10.1073/pnas.0400229101.
7. Ferreira J.L., Maslanka S., Johnson E., Goodnough M. Detection of botulinal neurotoxins A, B, E, and F by amplified enzyme-linked immunosorbent assay: collaborative study. Journal of AOAC International 2003, 86(2):314-331.
8. Gilmore M.A., Williams D., Okawa Y., Holguin B., James N.G., Ross J.A., et al. Depolarization after resonance energy transfer (DARET): a sensitive fluorescence-based assay for botulinum neurotoxin protease activity. Analytical Biochemistry 2011, 413(1):36-42. 10.1016/j.ab.2011.01.043.
9. Hallis B., James B.A., Shone C.C. Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities. Journal of Clinical Microbiology 1996, 34(8):1934-1938. [Research Support, Non-U.S. Gov't].
10. Laemmli U.K., Beguin F., Gujer-Kellenberger G. A factor preventing the major head protein of bacteriophage T4 from random aggregation. Journal of Molecular Biology 1970, 47(1):69-85.
11. Lakowicz J.R. Principles of fluorescence spectroscopy 1986, Plenum Press, New York, NY.
12. Pellett S., Tepp W.H., Toth S.I., Johnson E.A. Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination. Journal of Pharmacological and Toxicological Methods 2010, 61(3):304-310. [Comparative Study Research Support, Non-U.S. Gov't]. 10.1016/j.vascn.2010.01.003.
13. Sakaguchi G. Clostridium botulinum toxins. Pharmacology and Therapeutics 1982, 19(2):165-194. [Review].
14. Schmidt J.J., Stafford R.G. Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. Applied and Environmental Microbiology 2003, 69(1):297-303.
15. Simpson L.L. Identification of the major steps in botulinum toxin action. Annual Review of Pharmacology and Toxicology 2004, 44:167-193. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review]. 10.1146/annurev.pharmtox.44.101802.121554.
16. Simpson L.L., Maksymowych A.B., Kouguchi H., Dubois G., Bora R.S., Joshi S. The role of exoproteases in governing intraneuronal metabolism of botulinum toxin. The Protein Journal 2005, 24(3):155-165. 10.1007/s10930-005-7839-0.
17. Simpson L.L., Maksymowych A.B., Park J.B., Bora R.S. The role of the interchain disulfide bond in governing the pharmacological actions of botulinum toxin. Journal of Pharmacology and Experimental Therapeutics 2004, 308(3):857-864. [In Vitro Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 10.1124/jpet.103.058149.
18. Simpson L.L., Schmidt J.J., Middlebrook J.L. Isolation and characterization of the botulinum neurotoxins. Methods in Enzymology 1988, 165:76-85.
19. Takahashi T., Joshi S.G., Al-Saleem F., Ancharski D., Singh A., Nasser Z., et al. Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin. Vaccine 2009, 27(19):2616-2624. [Research Support, N.I.H., Extramural]. 10.1016/j.vaccine.2009.02.051.